A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis

Digestive and Liver Disease

Volumn 39, Issue 6, 2007, Pages 544-548

  Floreani, A ^a   Carderi, I ^a   Ferrara, F ^a   Rizzotto, E R ^a   Luisetto, G ^a   Camozzi, V ^a   Baldo, V ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bisphosphonates; Osteoporosis; Primary biliary cirrhosis

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM CARBONATE; CLODRONIC ACID; COLECALCIFEROL; OSTEOCALCIN; PARATHYROID HORMONE; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BONE DENSITY; BONE MASS; BONE METABOLISM; CONTROLLED STUDY; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; HUMAN; LINEAR REGRESSION ANALYSIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIMARY BILIARY CIRRHOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCIUM; CLODRONIC ACID; DIETARY SUPPLEMENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS, BILIARY; MIDDLE AGED; TREATMENT FAILURE; VITAMIN D;

EID: 34248581905     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2007.02.005     Document Type: Article

References (19)

1. Hay J.E. Osteoporosis in liver disease and after liver transplantation. J Hepatol 38 (2003) 856-865
2. OrmarS.D.ottir S., Ljunggren O., Mallmin H., Brahm H., and Loof L. Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease. J Hepatol 31 (1999) 84-90
3. Moschen A.R., Kaser A., Stadlmann S., Millonig G., Kaser S., Muhllechner P., et al. The RANK/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol 43 (2005) 973-983
4. Springer J.E., Cole D.E., Rubin L.A., Auch-Dudek K., Harewood L., Evroski J., et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 118 (2000) 145-151
5. American Gastroenterological Association Medical Position Statement. Osteoporosis in hepatic disorders. Gastroenterology 125 (2003) 937-940
6. Collier J.D., Ninkovic M., and Compston J.E. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 50 Suppl. I (2002) i1-i9
7. Zimolo Z, Welosowski G, Rodan GA. Acid extrusion is induced by osteoclast attachment to bone: inhibition by alendronate and calcitonin. J Clin Invest 96;2277-83.
8. NIH Consensus Conference Development panel on optimal calcium intake. J Am Med Assoc 272: 1924-1948, 1994.
9. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003;125:941-66.
10. Guanabens N., Pares A., Ros I., Alvarez L., Pons F., Caballeria L., et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 98 (2003) 2268-2274
11. Zein C.O., Jorgensen R.A., Clarke B., Wenger D.E., Keach J.C., Angulo P., et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 42 (2005) 762-771
12. Kaufman J.M., Devogelaer J.P., Raeman F., Rozenberg S., Body J.J., Westhovens R., et al. Prevention and treatment of post-menopausal osteoporosis national consensus of the 'Belgian Bone Club'. Clin Rheumatol 16 (1997) 343-345
13. Consensus Development Conference on Osteoporosis Hong Kong April 1-2, 1993. Am J Med 2003;95:1S-78S.
14. Heathcote J. Treatment of primary biliary cirrhosis. J Gastroenterol Hepatol 11 (1996) 605-609
15. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 288 (2002) 321-333
16. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. The heart and estrogen/progestin replacement study (HERS) research group. J Am Med Assoc 280 (1998) 605-613
17. Boonen S., Body J.-J., Boutsen Y., Devogelaer J.-P., Goemaere S., Kaufman J.-M., et al. Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 16 (2005) 239-254
18. Crippin J.S., Jorgensen R.A., Dickson E.R., and Lindor K.D. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 89 (1994) 47-50
19. Olsson R., Mattsson L.A., Obrant K., and Mellstrom D. Estrogen-progesteron therapy for low bone mineral density in primary biliary cirrhosis. Liver 19 (1999) 188-192